<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20250122031423&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20250122031423&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 22 Jan 2025 08:14:23 +0000</lastbuilddate>
<pubDate>Tue, 21 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39836093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 21:ehaf013. doi: 10.1093/eurheartj/ehaf013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39836093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39836093</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf013>10.1093/eurheartj/ehaf013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39836093</guid>
<pubDate>Tue, 21 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2025-01-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?</dc:title>
<dc:identifier>pmid:39836093</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf013</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: A CLEAR message questions the routine use of spironolactone in acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39836081/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 21:ehae936. doi: 10.1093/eurheartj/ehae936. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39836081/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39836081</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae936>10.1093/eurheartj/ehae936</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39836081</guid>
<pubDate>Tue, 21 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2025-01-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: A CLEAR message questions the routine use of spironolactone in acute myocardial infarction</dc:title>
<dc:identifier>pmid:39836081</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae936</dc:identifier>
</item>
<item>
<title>Non-Canonical TERT Activity Initiates Osteogenesis in Calcific Aortic Valve Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39835393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TERT's noncanonical activity is required to initiate calcification. TERT is upregulated via inflammatory signaling pathways and partners with STAT5 to bind the RUNX2 gene promoter. These data identify a novel mechanism and potential therapeutic target to decrease vascular calcification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 21. doi: 10.1161/CIRCRESAHA.122.321889. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Calcific aortic valve disease is the pathological remodeling of valve leaflets. The initial steps in valve leaflet osteogenic reprogramming are not fully understood. As TERT (telomerase reverse transcriptase) overexpression primes mesenchymal stem cells to differentiate into osteoblasts, we investigated whether TERT contributes to the osteogenic reprogramming of valve interstitial cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Human control and calcific aortic valve disease aortic valve leaflets and patient-specific human aortic valve interstitial cells were used in in vivo and in vitro calcification assays. Loss of function experiments in human aortic valve interstitial cells and cells isolated from <i>Tert</i><sup><i>-/-</i></sup> and <i>Terc</i><sup><i>-/-</i></sup> mice were used for mechanistic studies. Calcification was assessed in <i>Tert</i><sup><i>+/+</i></sup> and <i>Tert</i><sup><i>-/-</i></sup> mice ex vivo and in vivo. In silico modeling, proximity ligation, and coimmunoprecipitation assays defined novel TERT interacting partners. Chromatin immunoprecipitation and cleavage under targets and tagmentation sequencing defined protein-DNA interactions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: TERT protein was highly expressed in calcified valve leaflets without changes in telomere length, DNA damage, or senescence markers, and these features were retained in isolated primary human aortic valve interstitial cells. <i>TERT</i> expression increased with osteogenic or inflammatory stimuli, and knockdown or genetic deletion of <i>TERT</i> prevented calcification in vitro and in vivo. Mechanistically, TERT was upregulated via NF-κB and required to initiate osteogenic reprogramming, independent of its canonical reverse transcriptase activity and the long noncoding RNA <i>TERC</i>. TERT exerts noncanonical osteogenic functions via binding with STAT5 (signal transducer and activator of transcription 5). Depletion or inhibition of STAT5 prevented calcification. STAT5 was found to bind the promoter region of RUNX2 (runt-related transcription factor 2), the master regulator of osteogenic reprogramming. Finally, we demonstrate that TERT and STAT5 are upregulated and colocalized in calcific aortic valve disease tissue compared with control tissue.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TERT's noncanonical activity is required to initiate calcification. TERT is upregulated via inflammatory signaling pathways and partners with STAT5 to bind the RUNX2 gene promoter. These data identify a novel mechanism and potential therapeutic target to decrease vascular calcification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39835393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39835393</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.321889>10.1161/CIRCRESAHA.122.321889</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39835393</guid>
<pubDate>Tue, 21 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rolando A Cuevas</dc:creator>
<dc:creator>Luis Hortells</dc:creator>
<dc:creator>Claire C Chu</dc:creator>
<dc:creator>Ryan Wong</dc:creator>
<dc:creator>Alex Crane</dc:creator>
<dc:creator>Camille Boufford</dc:creator>
<dc:creator>Cailyn Regan</dc:creator>
<dc:creator>William J Moorhead Iii</dc:creator>
<dc:creator>Michael J Bashline</dc:creator>
<dc:creator>Aneesha Parwal</dc:creator>
<dc:creator>Angelina M Parise</dc:creator>
<dc:creator>Parya Behzadi</dc:creator>
<dc:creator>Mark J Brown</dc:creator>
<dc:creator>Aditi Gurkar</dc:creator>
<dc:creator>Dennis Bruemmer</dc:creator>
<dc:creator>John Sembrat</dc:creator>
<dc:creator>Ibrahim Sultan</dc:creator>
<dc:creator>Thomas G Gleason</dc:creator>
<dc:creator>Marie Billaud</dc:creator>
<dc:creator>Cynthia St Hilaire</dc:creator>
<dc:date>2025-01-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Non-Canonical TERT Activity Initiates Osteogenesis in Calcific Aortic Valve Disease</dc:title>
<dc:identifier>pmid:39835393</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.321889</dc:identifier>
</item>
<item>
<title>Rising Stars: Sean Zheng</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39834106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 21:ehae469. doi: 10.1093/eurheartj/ehae469. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39834106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39834106</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae469>10.1093/eurheartj/ehae469</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39834106</guid>
<pubDate>Tue, 21 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising Stars: Sean Zheng</dc:title>
<dc:identifier>pmid:39834106</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae469</dc:identifier>
</item>
<item>
<title>Interventions for adult congenital heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39833478/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>Advances in imaging diagnostics, surgical techniques and transcatheter interventions for paediatric patients with severe congenital heart disease (CHD) have substantially reduced mortality, thereby extending the lifespan of these individuals and increasing the number of adults with complex CHD. Transcatheter interventions have emerged as an alternative to traditional open-heart surgery to mitigate congenital defects. The evolution of techniques, the introduction of new devices and the growing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 20. doi: 10.1038/s41569-025-01118-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Advances in imaging diagnostics, surgical techniques and transcatheter interventions for paediatric patients with severe congenital heart disease (CHD) have substantially reduced mortality, thereby extending the lifespan of these individuals and increasing the number of adults with complex CHD. Transcatheter interventions have emerged as an alternative to traditional open-heart surgery to mitigate congenital defects. The evolution of techniques, the introduction of new devices and the growing experience of operators have enabled the treatment of patients with progressively more complex conditions. The general cardiology community might be less aware of contemporary interventions for adult CHD, their clinical indications and associated outcomes than interventional cardiologists and congenital heart specialists. In this Review, we provide a comprehensive evaluation of the available transcatheter interventions for adult patients with CHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39833478/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39833478</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01118-1>10.1038/s41569-025-01118-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39833478</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Pedro Cepas-Guillén</dc:creator>
<dc:creator>Eduardo Flores-Umanzor</dc:creator>
<dc:creator>Eric Horlick</dc:creator>
<dc:creator>Jamil Aboulhosn</dc:creator>
<dc:creator>Lee Benson</dc:creator>
<dc:creator>Xavier Freixa</dc:creator>
<dc:creator>Christine Houde</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Interventions for adult congenital heart disease</dc:title>
<dc:identifier>pmid:39833478</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01118-1</dc:identifier>
</item>
<item>
<title>Genetic testing in cardiomyopathies and new therapeutic target in cardiac remodelling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39832714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 21;46(4):333-336. doi: 10.1093/eurheartj/ehae890.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39832714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39832714</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae890>10.1093/eurheartj/ehae890</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39832714</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetic testing in cardiomyopathies and new therapeutic target in cardiac remodelling</dc:title>
<dc:identifier>pmid:39832714</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae890</dc:identifier>
</item>
<item>
<title>The gender gap following infrarenal abdominal aneurysm repair: how to close the gap?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39831896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 20:ehae874. doi: 10.1093/eurheartj/ehae874. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39831896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39831896</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae874>10.1093/eurheartj/ehae874</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39831896</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Chiara Lomazzi</dc:creator>
<dc:creator>Jasper F de Kort</dc:creator>
<dc:creator>Santi Trimarchi</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The gender gap following infrarenal abdominal aneurysm repair: how to close the gap?</dc:title>
<dc:identifier>pmid:39831896</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae874</dc:identifier>
</item>
<item>
<title>Obesity in familial hypercholesterolaemia: when precision medicine should meet precision population health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39831895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 20:ehae810. doi: 10.1093/eurheartj/ehae810. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39831895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39831895</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae810>10.1093/eurheartj/ehae810</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39831895</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jean-Pierre Després</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Obesity in familial hypercholesterolaemia: when precision medicine should meet precision population health</dc:title>
<dc:identifier>pmid:39831895</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae810</dc:identifier>
</item>
<item>
<title>Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39831819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrated that VEGF-A EV therapy offers efficient, dose-dependent VEGF-A protein formation with low immunogenicity, resulting in new vessel formation in murine models of ischaemic vascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 20:ehae883. doi: 10.1093/eurheartj/ehae883. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury. Target tissue delivery was verified by in situ analysis of protein and gene expression. Functional rescue was confirmed by in vivo imaging and histology. The safety of single and serial delivery was demonstrated using immune-based assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: VEGF-A EVs were generated with high mRNA content using a CNP methodology. VEGF-A EV administration demonstrated expression of exogenous VEGF-A mRNA by in situ RNA hybridization and elevated protein expression by western blot, microscopy, and enzyme-linked immunosorbent assay. Mice treated with human VEGF-A EVs after femoral or coronary artery ligation exhibited heightened neovascularization in ischaemic tissues with increased arterial perfusion and improvement in left ventricular function, respectively. Serial delivery of VEGF-EVs in injured skin showed improved wound healing with repeat administration. Importantly, as compared with adeno-associated viral and lipid nanoparticle VEGF-A gene therapy modalities, murine VEGF-A EV delivery did not trigger innate or adaptive immune responses at the injection site or systemically.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrated that VEGF-A EV therapy offers efficient, dose-dependent VEGF-A protein formation with low immunogenicity, resulting in new vessel formation in murine models of ischaemic vascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39831819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39831819</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae883>10.1093/eurheartj/ehae883</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39831819</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yi You</dc:creator>
<dc:creator>Yu Tian</dc:creator>
<dc:creator>Rui Guo</dc:creator>
<dc:creator>Junfeng Shi</dc:creator>
<dc:creator>Kwang Joo Kwak</dc:creator>
<dc:creator>Yuhao Tong</dc:creator>
<dc:creator>Andreanne Poppy Estania</dc:creator>
<dc:creator>Wei-Hsiang Hsu</dc:creator>
<dc:creator>Yutong Liu</dc:creator>
<dc:creator>Shijun Hu</dc:creator>
<dc:creator>Jianhong Cao</dc:creator>
<dc:creator>Liqun Yang</dc:creator>
<dc:creator>Rui Bai</dc:creator>
<dc:creator>Pufeng Huang</dc:creator>
<dc:creator>Ly James Lee</dc:creator>
<dc:creator>Wen Jiang</dc:creator>
<dc:creator>Betty Y S Kim</dc:creator>
<dc:creator>Shuhong Ma</dc:creator>
<dc:creator>Xujie Liu</dc:creator>
<dc:creator>Zhenya Shen</dc:creator>
<dc:creator>Feng Lan</dc:creator>
<dc:creator>Patricia Kim Phuong Nguyen</dc:creator>
<dc:creator>Andrew S Lee</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity</dc:title>
<dc:identifier>pmid:39831819</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae883</dc:identifier>
</item>
<item>
<title>Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39829438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 20. doi: 10.1161/CIRCULATIONAHA.124.070693. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The expression of the RGD (arginylglycylaspartic acid)-binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)-regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39829438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39829438</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070693>10.1161/CIRCULATIONAHA.124.070693</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39829438</guid>
<pubDate>Mon, 20 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sarah-Eve Lemay</dc:creator>
<dc:creator>Mónica S Montesinos</dc:creator>
<dc:creator>Yann Grobs</dc:creator>
<dc:creator>Tetsuro Yokokawa</dc:creator>
<dc:creator>Tsukasa Shimauchi</dc:creator>
<dc:creator>Manon Mougin</dc:creator>
<dc:creator>Charlotte Romanet</dc:creator>
<dc:creator>Mélanie Sauvaget</dc:creator>
<dc:creator>Sandra Breuils-Bonnet</dc:creator>
<dc:creator>Alice Bourgeois</dc:creator>
<dc:creator>Charlie Théberge</dc:creator>
<dc:creator>Andréanne Pelletier</dc:creator>
<dc:creator>Reem El Kabbout</dc:creator>
<dc:creator>Sandra Martineau</dc:creator>
<dc:creator>Keiko Yamamoto</dc:creator>
<dc:creator>Muzaffar Akram</dc:creator>
<dc:creator>Adrian S Ray</dc:creator>
<dc:creator>Blaise Lippa</dc:creator>
<dc:creator>Bryan Goodwin</dc:creator>
<dc:creator>Fu-Yang Lin</dc:creator>
<dc:creator>Hua Wang</dc:creator>
<dc:creator>James E Dowling</dc:creator>
<dc:creator>Min Lu</dc:creator>
<dc:creator>Qi Qiao</dc:creator>
<dc:creator>T Andrew McTeague</dc:creator>
<dc:creator>Terence I Moy</dc:creator>
<dc:creator>François Potus</dc:creator>
<dc:creator>Steeve Provencher</dc:creator>
<dc:creator>Olivier Boucherat</dc:creator>
<dc:creator>Sébastien Bonnet</dc:creator>
<dc:date>2025-01-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies</dc:title>
<dc:identifier>pmid:39829438</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070693</dc:identifier>
</item>
<item>
<title>Skeletal muscle adiposity in patients with impaired coronary flow reserve: risk marker, treatment target, or bystander?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39827906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 20:ehae909. doi: 10.1093/eurheartj/ehae909. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39827906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39827906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae909>10.1093/eurheartj/ehae909</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39827906</guid>
<pubDate>Sun, 19 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ranil de Silva</dc:creator>
<dc:creator>Kevin Cheng</dc:creator>
<dc:date>2025-01-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Skeletal muscle adiposity in patients with impaired coronary flow reserve: risk marker, treatment target, or bystander?</dc:title>
<dc:identifier>pmid:39827906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae909</dc:identifier>
</item>
<item>
<title>Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39827905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Increased intermuscular fat is associated with CMD and adverse cardiovascular outcomes independently of BMI and conventional risk factors. The presence of CMD and SM fat infiltration identified a novel at-risk cardiometabolic phenotype.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 20:ehae827. doi: 10.1093/eurheartj/ehae827. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Skeletal muscle (SM) fat infiltration, or intermuscular adipose tissue (IMAT), reflects muscle quality and is associated with inflammation, a key determinant in cardiometabolic disease. Coronary flow reserve (CFR), a marker of coronary microvascular dysfunction (CMD), is independently associated with body mass index (BMI), inflammation and risk of heart failure, myocardial infarction, and death. The relationship between SM quality, CMD, and cardiovascular outcomes is not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients (n = 669) undergoing evaluation for coronary artery disease with cardiac stress positron emission tomography demonstrating normal perfusion and preserved left ventricular ejection fraction were followed over a median of 6 years for major adverse cardiovascular events (MACEs), including death and hospitalization for myocardial infarction or heart failure. Coronary flow reserve was calculated as stress/rest myocardial blood flow. Subcutaneous adipose tissue (SAT), SM, and IMAT areas (cm2) were obtained from simultaneous positron emission tomography attenuation correction computed tomography using semi-automated segmentation at the 12th thoracic vertebra level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median age was 63 years, 70% were female, and 46% were nonwhite. Nearly half of patients were obese (46%, BMI 30-61 kg/m2), and BMI correlated highly with SAT and IMAT (r = .84 and r = .71, respectively, P &lt; .001) and moderately with SM (r = .52, P &lt; .001). Decreased SM and increased IMAT, but not BMI or SAT, remained independently associated with decreased CFR (adjusted P = .03 and P = .04, respectively). In adjusted analyses, both lower CFR and higher IMAT were associated with increased MACE [hazard ratio 1.78 (95% confidence interval 1.23-2.58) per -1 U CFR and 1.53 (1.30-1.80) per +10 cm2 IMAT, adjusted P = .002 and P &lt; .0001, respectively], while higher SM and SAT were protective [hazard ratio .89 (.81-.97) per +10 cm2 SM and .94 (.91-.98) per +10 cm2 SAT, adjusted P = .01 and .003, respectively]. Every 1% increase in fatty muscle fraction [IMAT/(SM + IMAT)] conferred an independent 2% increased odds of CMD [CFR &lt;2, odds ratio 1.02 (1.01-1.04), adjusted P = .04] and a 7% increased risk of MACE [hazard ratio 1.07 (1.04-1.09), adjusted P &lt; .001]. There was a significant interaction between CFR and IMAT, not BMI, such that patients with both CMD and fatty muscle demonstrated highest MACE risk (adjusted P = .02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Increased intermuscular fat is associated with CMD and adverse cardiovascular outcomes independently of BMI and conventional risk factors. The presence of CMD and SM fat infiltration identified a novel at-risk cardiometabolic phenotype.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39827905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39827905</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae827>10.1093/eurheartj/ehae827</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39827905</guid>
<pubDate>Sun, 19 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ana Carolina do A H Souza</dc:creator>
<dc:creator>Amelie S Troschel</dc:creator>
<dc:creator>Jan P Marquardt</dc:creator>
<dc:creator>Ibrahim Hadžić</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Filipe A Moura</dc:creator>
<dc:creator>Jon Hainer</dc:creator>
<dc:creator>Sanjay Divakaran</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:creator>Marcelo F Di Carli</dc:creator>
<dc:creator>Hugo J W L Aerts</dc:creator>
<dc:creator>Michael T Lu</dc:creator>
<dc:creator>Florian J Fintelmann</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:date>2025-01-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes</dc:title>
<dc:identifier>pmid:39827905</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae827</dc:identifier>
</item>
<item>
<title>Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39826545/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>The marking of DNA, histones, and RNA is central to gene expression regulation in development and disease. Recent evidence links N6-methyladenosine (m⁶A), installed on RNA by the METTL3-METTL14 methyltransferase complex, to histone modifications, but the link between m⁶A and DNA methylation remains scarcely explored. This study shows that METTL3-METTL14 recruits the DNA methyltransferase DNMT1 to chromatin for gene-body methylation. We identify a set of genes whose expression is fine-tuned by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 15:S0092-8674(24)01422-3. doi: 10.1016/j.cell.2024.12.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The marking of DNA, histones, and RNA is central to gene expression regulation in development and disease. Recent evidence links N6-methyladenosine (m<sup>6</sup>A), installed on RNA by the METTL3-METTL14 methyltransferase complex, to histone modifications, but the link between m<sup>6</sup>A and DNA methylation remains scarcely explored. This study shows that METTL3-METTL14 recruits the DNA methyltransferase DNMT1 to chromatin for gene-body methylation. We identify a set of genes whose expression is fine-tuned by both gene-body 5mC, which promotes transcription, and m<sup>6</sup>A, which destabilizes transcripts. We demonstrate that METTL3-METTL14-dependent 5mC and m<sup>6</sup>A are both essential for the differentiation of embryonic stem cells into embryoid bodies and that the upregulation of key differentiation genes during early differentiation depends on the dynamic balance between increased 5mC and decreased m<sup>6</sup>A. Our findings add a surprising dimension to our understanding of how epigenetics and epitranscriptomics combine to regulate gene expression and impact development and likely other biological processes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39826545/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39826545</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.009>10.1016/j.cell.2024.12.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39826545</guid>
<pubDate>Sat, 18 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Giuseppe Quarto</dc:creator>
<dc:creator>Andrea Li Greci</dc:creator>
<dc:creator>Martin Bizet</dc:creator>
<dc:creator>Audrey Penning</dc:creator>
<dc:creator>Irina Primac</dc:creator>
<dc:creator>Frédéric Murisier</dc:creator>
<dc:creator>Liliana Garcia-Martinez</dc:creator>
<dc:creator>Rodrigo L Borges</dc:creator>
<dc:creator>Qingzeng Gao</dc:creator>
<dc:creator>Pradeep K R Cingaram</dc:creator>
<dc:creator>Emilie Calonne</dc:creator>
<dc:creator>Bouchra Hassabi</dc:creator>
<dc:creator>Céline Hubert</dc:creator>
<dc:creator>Adèle Herpoel</dc:creator>
<dc:creator>Pascale Putmans</dc:creator>
<dc:creator>Frédérique Mies</dc:creator>
<dc:creator>Jérôme Martin</dc:creator>
<dc:creator>Louis Van der Linden</dc:creator>
<dc:creator>Gaurav Dube</dc:creator>
<dc:creator>Pankaj Kumar</dc:creator>
<dc:creator>Romuald Soin</dc:creator>
<dc:creator>Abhay Kumar</dc:creator>
<dc:creator>Anurag Misra</dc:creator>
<dc:creator>Jie Lan</dc:creator>
<dc:creator>Morgane Paque</dc:creator>
<dc:creator>Yogesh K Gupta</dc:creator>
<dc:creator>Arnaud Blomme</dc:creator>
<dc:creator>Pierre Close</dc:creator>
<dc:creator>Pierre-Olivier Estève</dc:creator>
<dc:creator>Elizabeth A Caine</dc:creator>
<dc:creator>Kristin M Riching</dc:creator>
<dc:creator>Cyril Gueydan</dc:creator>
<dc:creator>Danette L Daniels</dc:creator>
<dc:creator>Sriharsa Pradhan</dc:creator>
<dc:creator>Ramin Shiekhattar</dc:creator>
<dc:creator>Yael David</dc:creator>
<dc:creator>Lluis Morey</dc:creator>
<dc:creator>Jana Jeschke</dc:creator>
<dc:creator>Rachel Deplus</dc:creator>
<dc:creator>Evelyne Collignon</dc:creator>
<dc:creator>François Fuks</dc:creator>
<dc:date>2025-01-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation</dc:title>
<dc:identifier>pmid:39826545</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.009</dc:identifier>
</item>
<item>
<title>Passage of the HIV capsid cracks the nuclear pore</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39826544/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>Upon infection, human immunodeficiency virus type 1 (HIV-1) releases its cone-shaped capsid into the cytoplasm of infected T cells and macrophages. The capsid enters the nuclear pore complex (NPC), driven by interactions with numerous phenylalanine-glycine (FG)-repeat nucleoporins (FG-Nups). Whether NPCs structurally adapt to capsid passage and whether capsids are modified during passage remains unknown, however. Here, we combined super-resolution and correlative microscopy with cryoelectron...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 15:S0092-8674(24)01421-1. doi: 10.1016/j.cell.2024.12.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Upon infection, human immunodeficiency virus type 1 (HIV-1) releases its cone-shaped capsid into the cytoplasm of infected T cells and macrophages. The capsid enters the nuclear pore complex (NPC), driven by interactions with numerous phenylalanine-glycine (FG)-repeat nucleoporins (FG-Nups). Whether NPCs structurally adapt to capsid passage and whether capsids are modified during passage remains unknown, however. Here, we combined super-resolution and correlative microscopy with cryoelectron tomography and molecular simulations to study the nuclear entry of HIV-1 capsids in primary human macrophages. Our data indicate that cytosolically bound cyclophilin A is stripped off capsids entering the NPC, and the capsid hexagonal lattice remains largely intact inside and beyond the central channel. Strikingly, the NPC scaffold rings frequently crack during capsid passage, consistent with computer simulations indicating the need for NPC widening. The unique cone shape of the HIV-1 capsid facilitates its entry into NPCs and helps to crack their rings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39826544/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39826544</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.008>10.1016/j.cell.2024.12.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39826544</guid>
<pubDate>Sat, 18 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jan Philipp Kreysing</dc:creator>
<dc:creator>Maziar Heidari</dc:creator>
<dc:creator>Vojtech Zila</dc:creator>
<dc:creator>Sergio Cruz-León</dc:creator>
<dc:creator>Agnieszka Obarska-Kosinska</dc:creator>
<dc:creator>Vibor Laketa</dc:creator>
<dc:creator>Lara Rohleder</dc:creator>
<dc:creator>Sonja Welsch</dc:creator>
<dc:creator>Jürgen Köfinger</dc:creator>
<dc:creator>Beata Turoňová</dc:creator>
<dc:creator>Gerhard Hummer</dc:creator>
<dc:creator>Hans-Georg Kräusslich</dc:creator>
<dc:creator>Martin Beck</dc:creator>
<dc:date>2025-01-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Passage of the HIV capsid cracks the nuclear pore</dc:title>
<dc:identifier>pmid:39826544</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.008</dc:identifier>
</item>
<item>
<title>Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39826543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical practice. Herein, we successfully developed a recombinant Newcastle disease virus with porcine α1,3GT gene (NDV-GT) triggering hyperacute rejection. We demonstrated its feasibility in preclinical studies. The intravenous NDV-GT showed superior ability to eradicate tumor cells in our innovative...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 15:S0092-8674(24)01423-5. doi: 10.1016/j.cell.2024.12.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical practice. Herein, we successfully developed a recombinant Newcastle disease virus with porcine α1,3GT gene (NDV-GT) triggering hyperacute rejection. We demonstrated its feasibility in preclinical studies. The intravenous NDV-GT showed superior ability to eradicate tumor cells in our innovative CRISPR-mediated primary hepatocellular carcinoma monkeys. Importantly, the interventional clinical trial treating 20 patients with relapsed/refractory metastatic cancer (Chinese Clinical Trial Registry of WHO, ChiCTR2000031980) showed a high rate (90.00%) of disease control and durable responses, without serious adverse events and clinically functional neutralizing antibodies, further suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of NDV-GT for immunovirotherapy. Collectively, our results demonstrate the high safety and efficacy of intravenous NDV-GT, thus providing an innovative technology for OV therapy in oncological therapeutics and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39826543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39826543</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.010>10.1016/j.cell.2024.12.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39826543</guid>
<pubDate>Sat, 18 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Liping Zhong</dc:creator>
<dc:creator>Lu Gan</dc:creator>
<dc:creator>Bing Wang</dc:creator>
<dc:creator>Tao Wu</dc:creator>
<dc:creator>Fei Yao</dc:creator>
<dc:creator>Wenlin Gong</dc:creator>
<dc:creator>Hongmei Peng</dc:creator>
<dc:creator>Zhiming Deng</dc:creator>
<dc:creator>Guoyou Xiao</dc:creator>
<dc:creator>Xiyu Liu</dc:creator>
<dc:creator>Jintong Na</dc:creator>
<dc:creator>Desong Xia</dc:creator>
<dc:creator>Xianjun Yu</dc:creator>
<dc:creator>Zhikun Zhang</dc:creator>
<dc:creator>Bangde Xiang</dc:creator>
<dc:creator>Yu Huo</dc:creator>
<dc:creator>Dan Yan</dc:creator>
<dc:creator>Zhixin Dong</dc:creator>
<dc:creator>Fang Fang</dc:creator>
<dc:creator>Yun Ma</dc:creator>
<dc:creator>Guanqiao Jin</dc:creator>
<dc:creator>Danke Su</dc:creator>
<dc:creator>Xiuli Liu</dc:creator>
<dc:creator>Qiang Li</dc:creator>
<dc:creator>Hai Liao</dc:creator>
<dc:creator>Chao Tang</dc:creator>
<dc:creator>Jian He</dc:creator>
<dc:creator>Zhiping Tang</dc:creator>
<dc:creator>Shilai Zhang</dc:creator>
<dc:creator>Bingqing Qiu</dc:creator>
<dc:creator>Zhi Yang</dc:creator>
<dc:creator>Lihui Yang</dc:creator>
<dc:creator>Ziqin Chen</dc:creator>
<dc:creator>Mengsi Zeng</dc:creator>
<dc:creator>Ronghua Feng</dc:creator>
<dc:creator>Jiege Jiao</dc:creator>
<dc:creator>Yuan Liao</dc:creator>
<dc:creator>Tinghua Wang</dc:creator>
<dc:creator>Liangliang Wu</dc:creator>
<dc:creator>Zhengcheng Mi</dc:creator>
<dc:creator>Ziqun Liu</dc:creator>
<dc:creator>Si Shi</dc:creator>
<dc:creator>Kun Zhang</dc:creator>
<dc:creator>Wei Shi</dc:creator>
<dc:creator>Yongxiang Zhao</dc:creator>
<dc:date>2025-01-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients</dc:title>
<dc:identifier>pmid:39826543</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.010</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39824219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 18:ehae877. doi: 10.1093/eurheartj/ehae877. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39824219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39824219</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae877>10.1093/eurheartj/ehae877</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39824219</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</dc:title>
<dc:identifier>pmid:39824219</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae877</dc:identifier>
</item>
<item>
<title>SMC motor proteins extrude DNA asymmetrically and can switch directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39824185/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>Structural maintenance of chromosomes (SMC) complexes organize the genome via DNA loop extrusion. Although some SMCs were reported to do so symmetrically, reeling DNA from both sides into the extruded DNA loop simultaneously, others perform loop extrusion asymmetrically toward one direction only. The mechanism underlying this variability remains unclear. Here, we examine the directionality of DNA loop extrusion by SMCs using in vitro single-molecule experiments. We find that cohesin and SMC5/6...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 10:S0092-8674(24)01433-8. doi: 10.1016/j.cell.2024.12.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Structural maintenance of chromosomes (SMC) complexes organize the genome via DNA loop extrusion. Although some SMCs were reported to do so symmetrically, reeling DNA from both sides into the extruded DNA loop simultaneously, others perform loop extrusion asymmetrically toward one direction only. The mechanism underlying this variability remains unclear. Here, we examine the directionality of DNA loop extrusion by SMCs using in vitro single-molecule experiments. We find that cohesin and SMC5/6 do not reel in DNA from both sides, as reported before, but instead extrude DNA asymmetrically, although the direction can switch over time. Asymmetric DNA loop extrusion thus is the shared mechanism across all eukaryotic SMC complexes. For cohesin, direction switches strongly correlate with the turnover of the subunit NIPBL, during which DNA strand switching may occur. Apart from expanding by extrusion, loops frequently diffuse and shrink. The findings reveal that SMCs, surprisingly, can switch directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39824185/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39824185</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.020>10.1016/j.cell.2024.12.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39824185</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Roman Barth</dc:creator>
<dc:creator>Iain F Davidson</dc:creator>
<dc:creator>Jaco van der Torre</dc:creator>
<dc:creator>Michael Taschner</dc:creator>
<dc:creator>Stephan Gruber</dc:creator>
<dc:creator>Jan-Michael Peters</dc:creator>
<dc:creator>Cees Dekker</dc:creator>
<dc:date>2025-01-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SMC motor proteins extrude DNA asymmetrically and can switch directions</dc:title>
<dc:identifier>pmid:39824185</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.020</dc:identifier>
</item>
<item>
<title>Spatiotemporal and genetic cell lineage tracing of endodermal organogenesis at single-cell resolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39824184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>During early mammalian development, the endoderm germ layer forms the foundation of the respiratory and digestive systems through complex patterning. This intricate process, guided by a series of cell fate decisions, remains only partially understood. Our study introduces innovative genetic tracing codes for 14 distinct endodermal regions using novel mouse strains. By integrating high-throughput and high-precision single-cell RNA sequencing with sophisticated imaging, we detailed the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 12:S0092-8674(24)01425-9. doi: 10.1016/j.cell.2024.12.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During early mammalian development, the endoderm germ layer forms the foundation of the respiratory and digestive systems through complex patterning. This intricate process, guided by a series of cell fate decisions, remains only partially understood. Our study introduces innovative genetic tracing codes for 14 distinct endodermal regions using novel mouse strains. By integrating high-throughput and high-precision single-cell RNA sequencing with sophisticated imaging, we detailed the spatiotemporal and genetic lineage differentiation of the endoderm at single-cell resolution. We discovered an unexpected multipotentiality within early endodermal regions, allowing differentiation into various organ primordia. This research illuminates the complex and underestimated phenomenon where endodermal organs develop from multiple origins, prompting a reevaluation of traditional differentiation models. Our findings advance understanding in developmental biology and have significant implications for regenerative medicine and the development of advanced organoid models, providing insights into the intricate mechanisms that guide organogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39824184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39824184</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.012>10.1016/j.cell.2024.12.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39824184</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ke-Ran Li</dc:creator>
<dc:creator>Pei-Long Yu</dc:creator>
<dc:creator>Qi-Qi Zheng</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Xuan Fang</dc:creator>
<dc:creator>Lin-Chen Li</dc:creator>
<dc:creator>Cheng-Ran Xu</dc:creator>
<dc:date>2025-01-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatiotemporal and genetic cell lineage tracing of endodermal organogenesis at single-cell resolution</dc:title>
<dc:identifier>pmid:39824184</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.012</dc:identifier>
</item>
<item>
<title>A biophysical basis for the spreading behavior and limited diffusion of Xist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39824183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>Xist RNA initiates X inactivation as it spreads in cis across the chromosome. Here, we reveal a biophysical basis for its cis-limited diffusion. Xist RNA and HNRNPK together drive a liquid-liquid phase separation (LLPS) that encapsulates the chromosome. HNRNPK droplets pull on Xist and internalize the RNA. Once internalized, Xist induces a further phase transition and "softens" the HNRNPK droplet. Xist alters the condensate's deformability, adhesiveness, and wetting properties in vitro. Other...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 15:S0092-8674(24)01417-X. doi: 10.1016/j.cell.2024.12.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Xist RNA initiates X inactivation as it spreads in cis across the chromosome. Here, we reveal a biophysical basis for its cis-limited diffusion. Xist RNA and HNRNPK together drive a liquid-liquid phase separation (LLPS) that encapsulates the chromosome. HNRNPK droplets pull on Xist and internalize the RNA. Once internalized, Xist induces a further phase transition and "softens" the HNRNPK droplet. Xist alters the condensate's deformability, adhesiveness, and wetting properties in vitro. Other Xist-interacting proteins are internalized and entrapped within the droplet, resulting in a concentration of Xist and protein partners within the condensate. We attribute LLPS to HNRNPK's RGG and Xist's repeat B (RepB) motifs. Mutating these motifs causes Xist diffusion, disrupts polycomb recruitment, and precludes the required mixing of chromosomal compartments for Xist's migration. Thus, we hypothesize that phase transitions in HNRNPK condensates allow Xist to locally concentrate silencing factors and to spread through internal channels of the HNRNPK-encapsulated chromosome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39824183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39824183</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.004>10.1016/j.cell.2024.12.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39824183</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Mingrui Ding</dc:creator>
<dc:creator>Danni Wang</dc:creator>
<dc:creator>Hui Chen</dc:creator>
<dc:creator>Barry Kesner</dc:creator>
<dc:creator>Niklas-Benedikt Grimm</dc:creator>
<dc:creator>Uri Weissbein</dc:creator>
<dc:creator>Anna Lappala</dc:creator>
<dc:creator>Jiying Jiang</dc:creator>
<dc:creator>Carlos Rivera</dc:creator>
<dc:creator>Jizhong Lou</dc:creator>
<dc:creator>Pilong Li</dc:creator>
<dc:creator>Jeannie T Lee</dc:creator>
<dc:date>2025-01-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A biophysical basis for the spreading behavior and limited diffusion of Xist</dc:title>
<dc:identifier>pmid:39824183</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.004</dc:identifier>
</item>
<item>
<title>Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39824182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>In Huntington's disease (HD), striatal projection neurons (SPNs) degenerate during midlife; the core biological question involves how the disease-causing DNA repeat (CAG)(n) in the huntingtin (HTT) gene leads to neurodegeneration after decades of biological latency. We developed a single-cell method for measuring this repeat's length alongside genome-wide RNA expression. We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 14:S0092-8674(24)01379-5. doi: 10.1016/j.cell.2024.11.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In Huntington's disease (HD), striatal projection neurons (SPNs) degenerate during midlife; the core biological question involves how the disease-causing DNA repeat (CAG)<sub>n</sub> in the huntingtin (HTT) gene leads to neurodegeneration after decades of biological latency. We developed a single-cell method for measuring this repeat's length alongside genome-wide RNA expression. We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost. Our results suggest that somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously. We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene and that HD pathogenesis is a DNA process for almost all of a neuron's life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39824182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39824182</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.038>10.1016/j.cell.2024.11.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39824182</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Robert E Handsaker</dc:creator>
<dc:creator>Seva Kashin</dc:creator>
<dc:creator>Nora M Reed</dc:creator>
<dc:creator>Steven Tan</dc:creator>
<dc:creator>Won-Seok Lee</dc:creator>
<dc:creator>Tara M McDonald</dc:creator>
<dc:creator>Kiely Morris</dc:creator>
<dc:creator>Nolan Kamitaki</dc:creator>
<dc:creator>Christopher D Mullally</dc:creator>
<dc:creator>Neda R Morakabati</dc:creator>
<dc:creator>Melissa Goldman</dc:creator>
<dc:creator>Gabriel Lind</dc:creator>
<dc:creator>Rhea Kohli</dc:creator>
<dc:creator>Elisabeth Lawton</dc:creator>
<dc:creator>Marina Hogan</dc:creator>
<dc:creator>Kiku Ichihara</dc:creator>
<dc:creator>Sabina Berretta</dc:creator>
<dc:creator>Steven A McCarroll</dc:creator>
<dc:date>2025-01-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease</dc:title>
<dc:identifier>pmid:39824182</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.038</dc:identifier>
</item>
<item>
<title>Ages at coronary heart disease and death in familial hypercholesterolaemia: a Danish nationwide study spanning 44 years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39821644/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250122031423&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Nationwide from 1978 to 2021 in Denmark, normalization of age at death but not age at coronary heart disease was observed for individuals diagnosed with familial hypercholesterolaemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 17:ehae912. doi: 10.1093/eurheartj/ehae912. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Familial hypercholesterolaemia leads to lifelong elevated low-density lipoprotein cholesterol with increased risk of coronary heart disease and pre-mature death. It is unknown whether the prognosis for individuals with familial hypercholesterolaemia has improved over the past four decades as registration of this condition has been limited worldwide. However, in Danish nationwide registries, modified ICD coding has allowed such registration since 1978. This study tested the hypothesis that age at death and coronary heart disease has improved from 1978 to 2021 in individuals with vs. those without familial hypercholesterolaemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From nationwide registries, all Danish residents were included in a retrospective cohort study. Inclusion and follow-up were from 1978 to 2021. Individuals diagnosed with familial hypercholesterolaemia were identified, and trends over time were examined for age at death and age at coronary heart disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During follow-up for those with (n = 10 199) and without (n = 9 174 926) familial hypercholesterolaemia, 27% and 27% died and 34% and 9% experienced coronary heart disease. Age at death was 22 years younger in 1978 (P &lt; .001) but similar in 2021 (P = .16) in individuals with vs. without familial hypercholesterolaemia. Although the corresponding age at coronary heart disease was 20 years younger in 1978 (P &lt; .001), it was still 7 years younger in 2021 (P &lt; .001) in individuals with vs. without familial hypercholesterolaemia. These results were similar in women and men and in a 1:100 matched analysis by sex, ethnicity, and time of birth.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Nationwide from 1978 to 2021 in Denmark, normalization of age at death but not age at coronary heart disease was observed for individuals diagnosed with familial hypercholesterolaemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39821644/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250122031423&v=2.18.0.post9+e462414">39821644</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae912>10.1093/eurheartj/ehae912</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39821644</guid>
<pubDate>Fri, 17 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacob Reeh</dc:creator>
<dc:creator>Shoaib Afzal</dc:creator>
<dc:creator>Anders Berg Wulff</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:date>2025-01-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ages at coronary heart disease and death in familial hypercholesterolaemia: a Danish nationwide study spanning 44 years</dc:title>
<dc:identifier>pmid:39821644</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae912</dc:identifier>
</item>





























</channel>
</rss>